Find clinical trials

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Multiple doses of etentamig in combination with iberdomide will be explored. Each treatment arm receives a different dose of etentamig and iberdomide to determine a tolerable dose. Approximately 135 adult participants with R/R MM will be enrolled in the study in approximately 50 sites worldwide. In phase 1 participants will receive escalating intravenous (IV) etentamig in combination with oral iberdomide. In phase 2 participants will receive IV etentamig at one of two doses in combination with oral iberdomide, as part of the approximately 129 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and and monitoring of side effects.

Cardiac amyloidosis is an increasingly recognised cause of heart failure. This condition results in the heart becoming increasingly stiff and relying on an increased heart rate to maintain good heart function. Patients with pacemakers usually have their devices programmed to set their baseline heart rate at 60 beats per minute. There is growing evidence to suggest that patients with stiff hearts would have improved heart function and exercise capacity if the baseline heart rate was set closer to 75 beats per minute. This trial aims to determine if patients with cardiac amyloidosis who have a pacemaker have better heart function and quality of life if their pacemakers are set to a rate between 70 and 80 beats per minute compared to the standard 60 beats per minute.

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

The purpose of this trial is to find out whether a potential new treatment, the trial drug, Lu AF82422, is safe and effective in people living with Multiple Systems Atrophy (MSA). This trial will compare the effects of the trial drug, Lu AF82422, to placebo (inactive medication). Both the trial drug and placebo will be given as an infusion. Whether progression of MSA will be slowed is measured by a rating scale (questionnaire). The trial will also measure the amount of trial drug in participants blood and cerebrospinal fluid. Participants must have a reliable caregiver who will be available throughout the trial to complete caregiver observer questionnaires when carer/observer-reported outcomes are performed. The trial comprises 2 major periods: a 72-week double-blind PCP and an optional dose-blinded 72 week OLE period.